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1  | INTRODUC TION
Obesity is a worldwide epidemic. In 2005, 25% of the world pop-
ulation was overweight (as defined by body mass index [BMI] 25-
29.9 kg/m2) and 10% was obese (BMI > 30 kg/m2).1 By 2030, the 
prevalence is projected to reach 38% overweight and 20% obese. 
In the United States, the rates of obesity in 2014 were 35% of 
men and 40% of women.2 The health-related ramifications of 
obesity have been well documented, including but not limited 
to cardiovascular disease, diabetes mellitus (DM), and cancer.3-5 
In patients with end-organ disease, obesity-related comorbidi-
ties can influence access to transplant, technical aspects of the 
transplant operations, and posttransplant outcome. Although 
class 1 obesity (BMI 30-34.9 kg/m2) is not typically a contrain-
dication, class 2 (BMI 35-39.9 kg/m2) and class 3 (BMI > 40 kg/
m2) obesity can be relative or absolute contraindications to trans-
plant. Findings from a survey of American Society of Transplant 
Surgeons (ASTS) members administered by our task force showed 
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The increasing obesity epidemic has major implications in the realm of transplanta-
tion. Patients with obesity face barriers in access to transplant and unique challenges 
in perioperative and postoperative outcomes. Because of comorbidities associated 
with obesity, along with the underlying end-stage organ disease leading to trans-
plant candidacy, these patients may not even be referred for transplant evaluation, 
much less be waitlisted or actually undergo transplant. However, the use of bariat-
ric surgery in this population can help optimize the transplant candidacy of patients 
with obesity and end-stage organ disease and improve perioperative and postopera-
tive outcomes. We review the impact of obesity on kidney, liver, and cardiothoracic 
transplant candidates and recipients and explore potential interventions to address 
obesity in these populations.
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that for kidney transplant (KT) candidates, the average BMI cutoff 
considered to be a relative and absolute contraindication was 38 
and 41 kg/m2, respectively. For liver transplant (LT) candidates, 
these cutoffs were 40 and 45 kg/m2, and for thoracic transplant 
candidates, they were 35 and 38 kg/m2.
Optimal posttransplant outcomes are desirable for the individ-
ual recipient and from the perspective of responsible stewardship 
of limited donor organs. Studies examining the impact of obesity on 
transplant outcomes are limited by a lack of consensus not only of 
a commonly accepted definition of obesity but also of a standard 
approach to assessment of obesity. Despite these limitations, known 
comorbidities associated with obesity, such as DM, cardiovascular 
disease, obstructive sleep apnea, metabolic syndrome, and impaired 
pulmonary function, can affect transplant outcomes. These car-
diometabolic risks are compounded by the increased incidence of 
hyperlipidemia, hypertension, and DM observed with immunosup-
pressive drugs. Other considerations include the challenges of dos-
ing immunosuppressive and other medications, especially lipophilic 
agents that are affected by the variability in the volume of distribu-
tion in patients with obesity.
Given the impact of obesity on transplant outcomes, many trans-
plant centers have incorporated interventions that target obesity in 
their transplant candidates. Dietary education and interventions can 
be helpful but are resource intensive for a relatively modest level 
of impact.6 For those failing nutritional intervention and medical 
therapy, bariatric surgery can be helpful. Currently, the 2 predom-
inant procedures are laparoscopic sleeve gastrectomy (LSG) and 
laparoscopic Roux-en-Y gastric bypass (LRYGB). Although both 
procedures achieve 60%-80% excess body weight loss (%EBWL) 
within 18-24 months, the mechanism differs insofar as LSG is a re-
strictive procedure involving resection of the greater curve of the 
stomach and LRYGB is a restrictive/malabsorptive procedure that 
entails the creation of a gastric pouch and formation of a Roux-en-Y 
gastrojejunostomy.
The literature on patients with end-stage renal disease (ESRD) 
and concurrent obesity has generally shown bariatric surgery to 
have a positive impact on access to KT as well as posttransplant 
outcomes, but uncertainties remain regarding the optimal timing 
of bariatric surgery, either pretransplant or posttransplant. For 
KT candidates, 62.3% of transplant surgeons surveyed preferred 
bariatric surgery pretransplant, whereas 23.6% preferred post-
transplant bariatric surgery. For LT candidates, however, only 
29.0% and 30.3% of surgeons preferred bariatric surgery either 
pretransplant or posttransplant, respectively. This likely reflects 
the less robust evidence base for bariatric surgery in this patient 
population, with questions remaining regarding overall impact on 
transplant outcomes as well as appropriate timing of bariatric sur-
gery. For cardiothoracic transplant candidates, the literature is 
more limited regarding the use of bariatric surgery, as evidence 
is only beginning to emerge in this population. One potential 
benefit for early bariatric surgery, particularly for patients with 
chronic organ disease, is the potential for weight loss to prevent 
progression to end-stage organ failure.7 However, the focus of 
this report is that of patients who already have end-stage organ 
failure, and we do not cover the scope of chronic disease before 
organ failure.
With the pervasiveness of obesity in potential transplant candi-
dates, there is a need for increased awareness and further educa-
tion of all providers who care for this patient population. Of all ASTS 
members surveyed, only 64.2% of respondents expressed interest 
in attending a course to learn more about bariatric surgery and how 
to set up a bariatric transplant center. Here, we review the impact 
of obesity on KT, LT, and cardiothoracic transplant candidates and 
recipients and explore potential interventions to address obesity in 
these populations.
2  | KIDNE Y TR ANSPL ANT
2.1 | Access to KT
Like the rest of the US population, the ESRD population is becoming 
progressively more obese.8 Obesity-related comorbidities includ-
ing cardiovascular disease, DM, and cancer can all affect progres-
sion of chronic kidney disease (CKD) as well as morbidity preventing 
potential listing for kidney transplant (KT).3-5 However, there is an 
“obesity paradox” for patients on hemodialysis. There are data sug-
gesting that patients with higher BMIs (>27 to 27.8 kg/m2) have bet-
ter outcomes on dialysis compared with patients with lower BMIs 
(<21.8 to 23.1 kg/m2).9,10 In ESRD patients, higher BMI associated 
with visceral fat or abdominal obesity (potential indicators of meta-
bolic syndrome) increases the risk of DM and cardiovascular disease, 
whereas higher BMI with normal to high muscle mass or favorable 
waist circumference may confer some protection.4,11-17 Further com-
plicating the picture, it has been suggested that subcutaneous fat 
may be a marker of nutritional status in patients receiving hemodi-
alysis, whereas visceral fat may be associated with a more inflamma-
tory state.18,19
Despite the potential protective effect of obesity in patients on 
dialysis, KT still provides a clear survival advantage over dialysis.20 
Given these interacting factors, a more nuanced approach to the 
management of obesity is desirable to increase access to transplant, 
as well as increase the likelihood of operative technical success and 
long-term posttransplant outcomes. The use of weight assessment, 
often using BMI, is common, although controversial, and can occur 
even at the referral level.21-23
Once listed, patients with obesity continue to face lower rates of 
transplant and higher likelihood of organ offer bypass, and this is fur-
ther compounded by sex-related differences, with women less likely 
to be transplanted with BMI > 25 kg/m2.8,24 Paradoxically, programs 
that have become “more conservative” after receiving a low-perfor-
mance Scientific Registry of Transplant Recipients (SRTR) report are 
more likely to remove patients with BMI ≤ 24 kg/m2, rather than 
higher-BMI patients, suggesting an underlying appreciation for rea-
sonable outcomes in patients with obesity who are otherwise con-
sidered good surgical candidates.25
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2.2 | Graft and patient outcomes
The survival benefit of transplant over dialysis for patients with 
obesity has been established (Figure 1), although the benefit is 
lower at higher BMIs, particularly BMIs > 40 kg/m2, and there are 
suggestions that certain subgroups have inferior outcomes.20,26,27 
It is similarly well established that graft and patient survival 
rates in patients with obesity are inferior.28 This pattern follows 
a U-shaped distribution, as patients with either lower or higher 
than normal range BMI (either ≤20 or ≥26 kg/m2) have worse 
outcomes following transplant.6,29 These results are likely due to 
some combination of visceral fat effect, lean muscle mass or sar-
copenia, frailty, propensity for diabetes, and other obesity-related 
comorbidities.30,31 Interestingly, significant posttransplant weight 
gain (>20% in the first year or 10% in the second year) or weight 
loss (>5%) has been associated with decreased patient survival, 
suggesting that unintentional nutritional or metabolic states that 
result in large swings in weight are deleterious.32 Preexisting DM 
before transplant has also been associated with increased mortal-
ity in the first 10 years after transplant.33
Consistent with the model of obesity as an inflammatory state, 
obesity has been associated with increased biopsy-proven rejec-
tion, as well as delayed graft function.34-37 Posttransplant obesity 
or visceral adiposity is further associated with the development of 
cardiovascular disease, hypertension, and posttransplant DM.38,39 
Many of these comorbidities have an inflammatory component, 
which may be partially mitigated by controlled weight manage-
ment. Complicating this issue, obesity can also affect immuno-
suppression, with tacrolimus overdosing more common among 
patients with obesity.40
There are technical aspects to KT that can be more difficult with 
obesity. Some techniques, such as caval extensions in deceased donor 
right kidneys, have been developed to address these issues. However, 
particularly for those with obesity and significant iliac arterial disease, 
the operation is technically more challenging and occasionally prohib-
itive. Morbidity is affected—recipients with BMI values > 30 kg/m2  
may have up to a 4-fold increase in surgical site infections (SSIs) 
and a nearly 3-fold increase in hernias.41 The incidence of SSIs has 
been reported to range from 20% to 40% in recipients with BMI 
values > 40 kg/m2.42 Despite these complication risks, overall phys-
ical quality of life is similar for those who are overweight or obese 
following transplant, although costs are higher for those with BMI 
values > 40 kg/m2.43,44 Nonetheless, it is important to note that the 
presence of SSIs correlates with worse graft survival.45
The application of minimally invasive techniques to KT, such as 
robotic surgery, has shown promising results compared with open 
KT.46 Robot-assisted KT (RAKT) has resulted in statistically signif-
icant reduction in SSIs in a cohort of recipients with obesity.47,48 
Additionally, a matched-pair cohort study comparing recipients of 
robotic KT and a historical open KT cohort (28 patients each arm) 
found comparable patient and graft survival rates.46 RAKT seems 
to be a safe approach with a reduced complication rate in patients 
with obesity.
2.3 | Treatment options for KT patients with obesity
Weight loss is difficult, particularly for those with ESRD. For patients 
with obesity and CKD, particularly if on dialysis, pharmacological op-
tions are limited and usually ineffective. Traditionally, bariatric surgery 
has been thought to be risky for patients with CKD.49 However, as 
the preferred approach has migrated from LRYGB to LSG,50 there has 
been increased interest, particularly for patients requiring dialysis.51 For 
those patients with CKD who are predialysis, bariatric surgery may also 
improve effective renal function, with acceptable morbidity and mortal-
ity.52,53 Furthermore, pretransplant LSG increases access to the trans-
plant waitlist and improves posttransplant outcomes (Figure 2).54-56  
Granular studies on posttransplant bariatric surgery are small, but the 
F I G U R E  1   The survival benefit of kidney transplant in obese patients. The figure shows the multivariate adjusted hazard ratio for death 
in recipients of a living donor (LD; A), standard criteria deceased donor (SCD; B), and expanded criteria deceased donor (ECD; C) grouped by 
BMI compared with patients of the same BMI who had been on dialysis for equal lengths of time but had not yet received a kidney transplant 
(reference group denoted in blue with as relative risk of 1.0 in each figure). Reproduced from original publication Gill JS, et al. Am J Transplant. 
2013;13(8):2083-90. Reproduced with permission from Wiley Publishing Co [Color figure can be viewed at wileyonlinelibrary.com]
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risk profile appears to be acceptable, with similar improvement in co-
morbidities seen in solid organ transplant recipients as compared with 
the general population.57 A retrospective study evaluating bariatric sur-
gery before and after KT compared with propensity-matched nonbari-
atric surgery controls from the OPTN database found that those who 
underwent bariatric surgery (either before or after KT) had significantly 
decreased allograft failure and mortality.58 However, the risks of com-
plications and mortality after bariatric surgery in solid organ transplant 
recipients remain unclear and need further investigation.
2.4 | Conclusions and Recommendations
• KT results in a survival benefit compared with dialysis or wait-
listed patients in all classes of obesity.
• Patient and graft survival after KT exhibit a U-shaped phenome-
non, where those at either extreme of BMIs have impaired out-
comes, although survival benefit is still maintained.
• Pretransplant sleeve gastrectomy and Roux-en-Y gastric by-
pass have been shown to be safe and efficacious, in addition to 
increasing access to the transplant waitlist and improving post-
transplant outcomes.
• As the survival benefit of KT exists across BMIs, timing of KT 
relative to obesity intervention may be influenced by anticipated 
time on the transplant waitlist (or availability of living donors). For 
candidates with shorter anticipated wait times, proceeding with 
transplant followed by bariatric surgery is reasonable, but with 
longer anticipated wait times, the candidate may benefit from 
bariatric surgery first.
3  | LIVER TR ANSPL ANT
3.1 | Access to LT
The US obesity epidemic has led to a dramatic rise in obesity-related 
liver disease and the number of patients who require LT for decom-
pensated nonalcoholic fatty liver disease (NAFLD), nonalcoholic 
steatohepatitis (NASH), or associated hepatocellular carcinoma.59 
While only a minority of patients with obesity-related liver disease 
F I G U R E  2   A, Short-term outcomes 
in recipients of kidney transplant 
after undergoing laparoscopic sleeve 
gastrectomy (LSG) compared with 
controls (recipients of kidney transplants 
with similar BMI who did not undergo 
LSG). MI, myocardial infarction; CVA, 
cerebrovascular accident; TIA, transient 
ischemic attack. Reproduced from 
original publication Kim Y, et al. Am J 
Transplant. 2018;18(2):410-416. B, Long-
term outcomes in recipients of kidney 
transplant after undergoing laparoscopic 
sleeve gastrectomy (LSG) compared with 
controls (recipients of kidney transplants 
with similar BMI who did not undergo 
LSG). Abbrev. DGF: delayed graft 
function, NODAT: new-onset diabetes 
after transplant, SRTR: Scientific Registry 
of Transplant Recipients. Reproduced 
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(4% of NAFLD and 20% of NASH) will progress to cirrhosis and po-
tential consideration for LT, the vast number of patients affected by 
obesity drives the increased demand.60,61 In fact, NAFLD has be-
come the second most common indication for listing and the third 
most common indication for transplant.62,63
Despite the increased incidence of NAFLD and resultant need 
for transplant, an analysis of waiting list outcomes from 2002 to 
2006 demonstrated that patients with obesity were less likely 
to be listed for or undergo transplant.64 More detailed analysis 
demonstrated that this was at least partly due to fewer Model for 
End-Stage Liver Disease (MELD) exceptions being granted, along 
with a higher likelihood of offer rejections, resulting in a nearly 
30% lower transplant rate.64 The reluctance to consider patients 
with obesity for transplant may have been driven in part by initial 
SRTR data, which indicated reduced posttransplant survival for 
LT recipients with obesity.65 Importantly though, this study had 
a relatively small proportion of patients in the higher BMI cohorts 
(5% with BMI 35-40 kg/m2 and 2% with BMI > 40 kg/m2), with no 
adjustment for ascites. Subsequent analyses also using SRTR data 
based on a more contemporary data set, as well as a multicenter 
prospective database, demonstrated similar outcomes for both pa-
tient and graft survival for transplant recipients with and without 
obesity.26,66-68
3.2 | Graft and patient outcomes
Patients with obesity tend to gain weight after transplant and a sig-
nificant proportion develop metabolic syndrome.69 LT recipients 
who develop posttransplant metabolic syndrome have higher risk 
of vascular events (stroke, transient ischemic attacks, myocardial in-
farction, acute coronary syndrome, and sudden cardiac death).70 The 
increased incidence of posttransplant DM is also associated with de-
creased survival rate after LT.71
Surgical complications, including wound infections, dehiscence, 
biliary complications, and overall infection rate after LT are increased 
(in some studies 4- to 6-fold) in patients with BMI > 35 kg/m2.72,73 A 
number of studies have reported longer ICU and hospital lengths of 
stay (LOSs), as well as increased rates of discharge to a skilled nurs-
ing or rehabilitation facility in LT recipients with obesity.65,72,74,75 
Other studies have shown mixed outcomes in terms of both short-
term morbidity and long-term survival.65,68,76-78 Regardless of these 
varied results, recent cohorts suggest similar posttransplant survival 
between recipients with and without obesity.73,79 Furthermore, a 
survival benefit with LT is observed in candidates with all categories 
of obesity.26
Patients with obesity and NASH are reported by some groups 
to have equivalent graft and patient survival compared with those 
with other causes of liver disease.80,81 However, NASH recipients 
also had increased operative time, blood loss, and hospital LOS.81 
Another study noted that mortality within 4 months of LT was twice 
as high in patients with NASH compared with those without and that 
patients with obesity and NASH, along with a high-risk phenotype 
(age >60 years, BMI > 30 kg/m2, concomitant hypertension, and 
DM), had lower 5-year survival rates compared with NASH recipi-
ents without the phenotype.82
Future directions for research to guide patient selection and in-
terventions to optimize short- and long-term outcomes after LT in 
patients with obesity may benefit from a consensus conference to 
establish uniform (1) categories of obesity, (2) approaches to mea-
sure type (visceral/peripheral) and degree of obesity in patients with 
end-stage liver disease (ESLD), (3) assessment of key comorbidities 
associated with obesity and liver disease, (4) pretransplant and post-
transplant interventions to enhance muscle mass and mitigate met-
abolic syndrome including recurrent disease posttransplant, and (5) 
criteria to measure postintervention success.
3.3 | Treatment options for LT patients with obesity
Currently, options for managing obesity in the transplant population 
similar to the nontransplant population and includes diet, exercise, 
and bariatric surgery. Given the effect of obesity on perioperative 
and postoperative outcomes, weight loss is likely beneficial for LT 
recipients. However, optimal times for weight loss interventions and 
best method(s) remain unclear (Table 1).83
3.3.1 | Pretransplant obesity management
Certainly, management of obesity before transplant is beneficial as it 
can improve candidacy for transplant and reduce both the technical 
challenges of operating in patients with obesity and the attendant 
perioperative complications. While there is limited information re-
garding the effects of diet and exercise on pretransplant weight loss, 
a few studies have demonstrated the beneficial effect of both aero-
bic exercise and caloric restriction in patients with compensated cir-
rhosis vis-à-vis improved insulin resistance and liver enzymes, as well 
as decreased body fat and BMI.84-87 Two separate studies showed a 
loss of 10% total body weight to be associated with a reduction in 
fibrosis.88,89
Bariatric surgery may be feasible for patients with compensated 
cirrhosis, though it is less commonly an option for waitlisted patients 
given the risk of elective surgery for patients with decompensated 
liver disease. LSG has advantages over LRYGB in patients with com-
pensated cirrhosis given (1) the technical ease of the procedure and 
therefore shorter operative time and (2) preservation of the gastro-
intestinal tract for creation of a possible Roux-limb as part of an LT 
or maintenance of access for potential future therapeutic endoscopic 
interventions.55 Studies have shown the safety and efficacy of LSG 
in patients with ESLD.55,90 Short-term complications included bleed-
ing, wound infections, staple line leak, and hepatic encephalopathy, 
though there were not associated 30-day mortalities. The percent 
EBWL was 50%-62% at 1 year post LSG, and for those who underwent 
LT, this weight loss was maintained up to 1 year post LT, suggesting a 
protective effect of pretransplant LSG on posttransplant weight gain.
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TA B L E  1   Bariatric surgery and liver transplant case series, including those with pretransplant, simultaneous with transplant, and 
posttransplant bariatric surgery
Author Time range Cohort (n)
Bariatric procedure 
done
Timing of bariatric 
procedure to 
transplant Endpoints and notable findings
Lin et al55 2006-2012 SG pre–liver (n = 20) and kidney 
(n = 6) transplant
SG Pretransplant 7/20 transplanted, all met weight 
criteria. 1 staple line leak, 2 




2007-2017 Patients currently undergoing 
LT with remote history of prior 
bariatric surgery






Pretransplant 30 d re-op rate, biliary complications, 
patient and graft survival at 1 
and 2 y. No comparison group for 
complications, but similar patient/
graft survival to those without 
bariatric surgery
Takata et al90 2004-2007 Patients with cirrhosis (n = 6) who 
underwent SG
SG Pretransplant Complications, excess weight loss, 
obesity-related comorbidities, 
transplant candidacy. Excellent 
weight loss noted, though short 
follow-up. No major complications 




2006-2012 Obese patients undergoing LT 
who had a combined LT and SG 
(n = 7) and who had LT with no 
SG (N = 37)
SG Simultaneous Death, graft loss, operative 
complications were similar in two 
groups. Post LT metabolic outcomes 
superior in the combined group
Tariciotti 
et al93
2016 N = 1 obese patient with NAFLD 
and HCC undergoing combined 
LT + SG
SG Simultaneous Weight loss robust, no significant 
complications, follow-up only 5 mo, 
no comparison group
Nesher et al92 Not stated LT and simultaneous SG (n = 3) SG Simultaneous Normal allograft function, 
robust weight loss at 13 mo. No 
comparison group
Lin et al55 2007-2011 SG post LT (n = 8) SG Posttransplant 30-d complications include 3 re-
ops. Weight loss robust, allograft 
function normal, improved 
metabolic parameters
Osseis et al96 2008-2015 SG post LT (N = 6) SG Posttransplant Surgical outcomes, liver and kidney 
function tests, outcomes of obesity-




2010-2016 SG after LT (n = 12) and SG with 
no previous transplant (n = 36)
SG Posttransplant Case-control noted similar 
postoperative events, long-term 
weight loss, comorbidity resolution. 
Slightly longer hospital stay in those 
with prior LT
Elli et al98 2008-2014 Post solid organ transplant 
recipients undergoing sleeve 
gastrectomy and nontransplant 
patients undergoing sleeveb 
gastrectomy
Kidney transplant (n = 6)
Liver transplant (n = 2)
Pancreas transplant (n = 2)
SG Posttransplant Percentage excess weight loss, 
perioperative and postoperative 
complications
Khoraki et al97 2008-2014 Post solid organ transplant 
patients undergoing SG
Liver (n = 5)
Also heart and kidney patients 
reported (total 10)
SG Posttransplant Robust weight loss, resolution or 
improvement of obesity-related co 
morbidities, normal allograft function. 
Splenectomy required in LT recipient 
due to bleeding, with subsequent PV 
thrombosis and need for TIPS
(Continues)
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3.3.2 | Perioperative obesity management
Simultaneous bariatric surgery and LT (S-LT) is another approach to 
managing obesity in this patient population. The advantage of this 
approach includes addressing both obesity and liver disease in one 
operation, with potentially less patient discomfort and lower costs. 
The disadvantage lies in the fact that combining both surgeries 
creates a more complicated procedure. To examine this, Heimbach 
et al87 compared outcomes between LT candidates who lost weight 
preoperatively using lifestyle modification (n = 37) to those patients 
who underwent S-LT (n = 7) due to failure of lifestyle modification. 
Their results demonstrated that the cohort who had S-LT had nonin-
ferior perioperative outcomes despite having a significantly higher 
preoperative BMI. Specifically, in patients undergoing the combined 
procedures, there were no deaths or graft losses. Complications in-
cluded 1 leak from the gastric staple line and 1 patient with excess 
weight loss. There were no patients who developed posttransplant 
DM or steatosis, and all patients maintained substantial weight 
loss out to an average of 17 months (Figure 3). Taken together, 
this study suggests a role for bariatric surgery at the time of LT in 
carefully selected patients. A recent report from the same group 
reported on longer-term outcomes for 29 patients who underwent 
S-LT, including 13 patients more than 3 years out, demonstrating 
efficacy for achieving and maintaining weight loss as well as favora-
ble metabolic profiles for those who underwent S-LT.91 Two addi-
tional case reports of S-LT also supported safety and efficacy of the 
procedure.92,93 The first reported case of simultaneous SG with a 
living donor LT recipient was described in 2017, resulting in post-
transplant weight loss to BMI < 30 kg/m2 within 2 months, as well 
as cure of DM.94
3.3.3 | Posttransplant obesity management
A noninvasive, structured multidisciplinary weight loss program re-
mains the foundation of obesity management even in the posttrans-
plant setting. If not successful, which is more likely for patients with 
severe obesity, delayed bariatric surgery after LT (D-LT) may be con-
sidered. In a series of RYGB after LT (n = 7), Al-Nowaylati et al95 re-
ported effective weight loss but concerning results included 1 death 
and 1 reversal due to complications of bariatric surgery. A matched 
case-control series of LSG in patients with (n = 12) vs without prior 
LT (n = 36) noted similar operative times and postoperative morbidity 
with no conversion to open surgery, though with a longer hospital LOS 
in those with a prior LT.96 Other smaller series of D-LT note similar effi-
cacy with weight loss and metabolic complications, though adhesions, 
bleeding issues, and longer operative time were described.55,96-98
3.4 | Conclusions and recommendations
• Obesity-related liver disease is projected to become the leading 
indication for LT in the next decade in the United States.
• LT results in a survival benefit in all classes of obesity.
Author Time range Cohort (n)
Bariatric procedure 
done
Timing of bariatric 
procedure to 
transplant Endpoints and notable findings
Al-Nowaylati 
et al95
2001-2009 Patient who underwent open 
RYGB after OLT (n = 7)
RYGB Posttransplant Robust weight loss, improved glycemic 
control and Dyslipidemia control. 
One death and one reversal due to 
complications related to surgery
TA B L E  1   (Continued)
F I G U R E  3   BMI trends for those 
patients who underwent combined liver 
transplant plus sleeve gastrectomy (N = 7). 
Mean follow-up is 17 mo. Reproduced 
from original publication Heimbach JK, 
et al. Am J Transplant. 2013;13(2):363-
368 [Color figure can be viewed at 
wileyonlinelibrary.com]
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• Recommendations based on low-to-moderate grade evidence 
suggest sleeve gastrectomy as the preferred bariatric surgical 
technique in LT candidates or recipients.
• Future studies should investigate comparative effectiveness of bar-
iatric surgery timing in the LT population between S-LT and D-LT.
4  | C ARDIOTHOR ACIC TR ANSPL ANT
4.1 | Access to cardiothoracic transplant
As all healthcare providers know, obesity is an epidemic world-
wide, and this is no different in thoracic transplant. In a re-
cent survey of thoracic transplant surgeons (2018 Obesity in 
Transplantation Task Force Survey), 60% of programs have a BMI 
threshold with 33% being an absolute and 50% a relative con-
traindication. Of survey responders, 75% have intervention pro-
grams for obesity, spanning the spectrum of interventions from 
dietary and lifestyle modifications to medical and surgical inter-
ventions. The presence of obesity thresholds, as well as the hesi-
tancy of certain centers to surgically intervene on patients with 
both obesity and end-stage cardiopulmonary failure, significantly 
inhibits access to life-saving transplant therapies. If patients are 
able to be transplanted, their wait-time can be increased and ac-
cess to suitable organs limited.99
4.2 | Graft and patient outcomes
As with other transplants, there is a tendency of patients to gain 
weight post cardiothoracic transplant,100 and this can confound 
mobilization and infections. Functional status of patients with 
morbid obesity coupled with a risk for hidden sarcopenia drives 
a large portion of the concern. These patients with obesity have 
an increased risk for impaired sternal wound healing, with sternal 
nonunion/dehiscence,101-103 which is a problem even without the 
added burden of immunosuppression. In patients with left ventricu-
lar assist devices (LVADs), obesity is correlated with driveline infec-
tions104 which can also influence recovery after heart transplant.
The impact of obesity on outcomes posttransplant is not lim-
ited to the morbidity of wound healing but on survival as well.105 
Obesity predisposes recipients to increased cardiac allograft vas-
culopathy, cardiovascular diseases, and metabolic syndrome after 
heart transplant.106 Patients with obesity are also at a higher risk 
of posttransplant mortality in both heart and lung transplant.107-110 
These outcomes are accentuated in patients with idiopathic pulmo-
nary fibrosis where the risk of 90-day mortality is 1.71-fold higher 
with obesity, and this can significantly affect overall center per-
formance.107,108 Additionally, in LT recipients, obesity is associated 
with a significant 2-fold increase risk of primary graft dysfunction 
(PGD)111 within 72 hours posttransplant and there is an increased 
risk of 40% occurrence of PGD for each additional 5-kg/m2 increase 
in BMI.111
4.3 | Treatment options for cardiothoracic 
transplant patients with obesity
Treatment options for the patient with morbid obesity have relative 
pros and cons. Dietary, supplementation, and lifestyle modifica-
tions were used by all respondents in the ASTS Taskforce Survey. 
These approaches have some benefit, though the overall impact on 
the patient with end-stage cardiopulmonary failure can be limited. 
The relative sedentary nature of the disease courses, the impact on 
oxygen delivery, and limited mobility can hinder increased caloric 
expenditure (i.e., exercise). Socioeconomic impacts compound the 
issues. For many patients, the time-sensitive nature of their dis-
ease means that the likelihood of losing meaningful weight before 
becoming transplant ineligible is prohibitive. Pre–lung transplant 
weight loss significantly improves survival and decreases days on 
the ventilator,112 so any intervention resulting in weight loss can 
have significant impacts on outcomes and survival. Patients with 
morbid obesity who are able to undergo LSG can facilitate weight 
loss and improve eligibility for transplant.113,114 In patients with 
end-stage lung disease, select patients with obesity undergoing 
bariatric surgery can have improvement of their lung disease and 
function, as well as pulmonary hypertension, through the weight 
loss.115,116
In summary, obesity has significant negative impact on access 
to thoracic transplant. Furthermore, obesity negatively affects 
perioperative morbidity and mortality. When appropriate and fea-
sible, LSG provides a strategy to facilitate weight loss and improve-
ment in pretransplant symptoms and function as well as enhancing 
access.
4.4 | Conclusions and recommendations
• Bariatric surgery before thoracic transplant may lead to improved 
pulmonary function, access to transplant, and posttransplant 
outcomes.
5  | FINANCIAL CONSIDER ATIONS FOR 
OBESIT Y INTERVENTION
The ASTS has previously shared the high cost of patients on the 
transplant waitlist. For example, the cost of maintenance pre-
transplant hemodialysis can easily be as high as $260 000 per 
year per covered life.117 Even after transplant, average Medicare 
payments in the following 3 years after KT increase with higher 
BMI (Figure 4). LSG can have a significant positive financial and 
clinical impact in the KT population. Using LSG in a patient with 
obesity and advanced CKD or early ESRD can potentially allow 
these patients to be listed for a deceased donor KT or, even 
better, to receive a preemptive living donor KT. Additionally, 
small studies have shown that performing S-LT for patients with 
NASH prevents disease recurrence, thus avoiding the high cost 
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of potential graft failure and retransplant, with the 1-year ad-
ditional cost of liver graft failure >$150 000.91 In summary, con-
sideration of bariatric surgery in the transplant population has 
early potential to positively affect the transplant process finan-
cially. However, there is a need for well-designed clinical trials 
as well as cost-effectiveness studies to support broader payor 




Bariatric surgery may result in altered absorption of medications, in-
cluding immunosuppressive agents that are crucial in the posttrans-
plant setting. RYGB in KT candidates and recipients has been shown 
to result in higher requirements of cyclosporine as well as significant 
differences in pharmacokinetics of tacrolimus, sirolimus, mycophenolic 
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Average 3-Year Payments (n=3188)
Mean 3-year Payments N Mean Std. Deviation Std. Error
Lower Bound Upper Bound
BMI < 18.5 94 $109,623 $42,770 $4,411 $100,863 $118,383
BMI 18.5 - 24.9 1127 $115,400 $50,487 $1,504 $112,449 $118,351
BMI 25.0 - 29.9 1072 $116,028 $50,887 $1,554 $112,978 $119,077
BMI 30.0- 34.9 635 $116,588 $49,965 $1,983 $112,694 $120,481
BMI 35.0 - 39.9 194 $127,196 $53,589 $3,847 $119,607 $134,784
BMI > 40.0 66 $143,529 $74,969 $9,228 $125,099 $161,959
Total 3188 $116,977 $51,314 $909 $115,195 $118,759

























Average 3-Year Payments: Deceased Donor 
Recipient (n=8663)
Mean 3-year Payments N Mean Std. Dev Std. Error
Lower Bound Upper Bound
BMI < 18.5 196 $109,795 $60,324 $4,309 $101,297 $118,293
BMI 18.5 - 24.9 2758 $114,547 $92,517 $1,762 $111,093 $118,002
BMI 25.0 - 29.9 3014 $114,146 $67,433 $1,228 $111,737 $116,554
BMI 30.0- 34.9 1824 $121,231 $75,451 $1,767 $117,766 $124,696
BMI 35.0 - 39.9 667 $125,223 $75,893 $2,939 $119,453 $130,993
BMI > 40.0 204 $133,519 $78,385 $5,488 $122,698 $144,340
Total 8663 $116,976 $78,704 $846 $115,319 $118,634
95% CI for Mean
A
B
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acid, and mycophenolic acid glucuronide compared with nonbypass 
patients.118,119 KT candidates who underwent LSG did not appear to 
have significantly different pharmacokinetics of tacrolimus (immediate 
or extended release) or mycophenolic acid, suggesting that post-LSG 
patients may not require dose modification out of the norm for trans-
plant recipients.120 However, a larger series demonstrated that both 
RYGB and LSG could be performed without requiring significant dos-
age adjustments of tacrolimus, mycophenolic acid, or prednisone, and 
indeed, stability of blood trough levels increased after bariatric sur-
gery.57 Therefore, with appropriate monitoring, immunosuppression 
may be well maintained in recipients of both RYGB and LSG.
7  | CONCLUSIONS AND FUTURE 
DIREC TIONS
Patients with obesity and concurrent end-stage organ failure face 
significant challenges in access to transplant as well as negative im-
pacts on outcomes after solid organ transplant. Addressing obesity 
in select patients with bariatric surgery before transplant may im-
prove access, facilitate an easier operation, as well as improve ben-
efits of transplant. Bariatric surgery after transplant may also help 
to enhance the benefits from transplant under certain situations. 
Further investigation is needed to clarify optimal timing of bariat-
ric surgery relative to transplant, as well as to evaluate the role of 
bariatric surgery for chronic organ disease before development of 
end-stage organ failure, and to assess the role of bariatric surgery for 
potential living donors with obesity.
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